Textbook Notes (270,000)
CA (160,000)
Ryerson (10,000)
PAT (70)
Chapter N/A

PAT 20A/B Chapter Notes - Chapter N/A: Diphenhydramine, Monoclonal Antibody, Bevacizumab

Course Code
Audrey Kenmir

This preview shows half of the first page. to view the full 3 pages of the document.
(2)PAT20 Winter Week 10 Drug Classifications ( Colorectal Cancer )
1. Monoclonal Anti-Body (Anti-cancer cells)
Monoclonal antibody drugs: bevacizumab (Avastin)
Action: an antibody that marks the cancer cell and makes it easier for the immune system
to find, monoclonal antibodies can block these receptors and prevent the growth signal
from getting through, block these growth signals to help prevent a tumor from developing
a blood supply so that it remains small, combining a radioactive particle with a
monoclonal antibody can deliver radiation and chemotherapy directly to the cancer cells.
Uses: used in combination with other treatments, such as chemotherapy and hormone
therapy to treat cancer.
Pharmacokinetics (Bevacizumab):
Side/Adverse Effects:
Allergic reactions, such as hives or itching; flu-like signs and symptoms, including chills,
fatigue, fever, and muscle aches and pains; nausea; diarrhea; skin rashes
Allergic to bevacizumab, have slow healing of a skin wound or surgical incision; have
had surgery within the past 4 weeks (28 days); have recently been coughing up blood; or
you plan to have surgery within the next 4 weeks (28 days); heart disease, high blood
pressure; history of heart attack, stroke, or blood clots; bleeding or blood-clotting
disorder; or history of stomach or intestinal bleeding, or perforation (a hole or tear) in
your esophagus, stomach, or intestines
-Some products that may interact with this drug include: sunitinib.
Dosages (Bavacizumab):
Liquid = 25 mg/mL
Nursing Management Priorities:
Assess: history of hypersensitivity, allergy
You're Reading a Preview

Unlock to view full version